Clinical Trials Logo

Melanosis clinical trials

View clinical trials related to Melanosis.

Filter by:

NCT ID: NCT01993654 Terminated - Nevus Clinical Trials

In Vivo Confocal Microscopy Study of Pigmented Conjunctival Lesions

Start date: September 2011
Phase: N/A
Study type: Observational

This study aims to validate the use of laser in vivo confocal microscopy as an early diagnostic and differentiation tool of pigmented conjunctival lesions, evaluate the efficacy of in vivo confocal microscopy for follow-up (as a visualizing tool) after tumor resection for early detection of tumor recurrence, and to evaluate the use of in vivo confocal microscopy in evaluation of response to treatment. The modified technique with Heidelberg Retina Tomography (HRT) confocal microscopy and anterior segment optical coherence tomography (OCT) are non-invasive, no-touch, imaging techniques that may help in differentiation of benign lesions like nevi or racial melanosis, from malignant lesions like primary acquired melanosis and malignant melanomas. The OCT will potentially allow to estimate tumor depth in vivo as preliminary studies have shown.

NCT ID: NCT01976286 Active, not recruiting - Melanosis Clinical Trials

A Pilot Study Testing Salicylic Acid Peels Versus Glycolic Acid Peels for the Treatment of Melasma

Start date: January 2015
Phase: N/A
Study type: Interventional

The purpose of this study is to find out the safety and effectiveness of Glycolic Acid Chemical Peels compared to Salicylic Acid Chemical Peels for the treatment of melasma.

NCT ID: NCT01976273 Completed - Melanosis Clinical Trials

A Pilot Study Testing 1064nm Q-switch Laser Versus Glycolic Acid Peels for the Treatment of Melasma

Start date: October 2013
Phase: N/A
Study type: Interventional

The purpose of this study is to find out the safety and effectiveness of 1064 Q-Switch Laser Therapy compared to Glycolic Acid Chemical Peels for the treatment of melasma.

NCT ID: NCT01745224 Terminated - Melasma Clinical Trials

Revlite Laser System Compared to the Candela Alex TriVantage System Refractory Mixed Type Melasma

Start date: July 2012
Phase: N/A
Study type: Interventional

This proof of concept study will be conducted to assess the aesthetic improvement in refractory mixed type melasma in subjects treated with two FDA 510K approved devices: Q Switched Nd: YAG Laser vs. Alex TriVantage

NCT ID: NCT01442727 Completed - Arsenical Keratosis Clinical Trials

Selenium in the Treatment of Arsenic Toxicity and Cancers

SETAC
Start date: December 2006
Phase: Phase 3
Study type: Interventional

Context: Approximately 100 million people throughout the world consume water contaminated with arsenic at levels above carcinogenic thresholds, including 40 million in Bangladesh alone, with up to one-fourth of deaths attributed to arsenic exposure in the worst-affected regions. There are no proven therapies for treating chronic arsenic toxicity or for preventing arsenical cancers. Selenium has been known to counter arsenic toxicity in a variety of animal models. The investigators have recently shown in animals and humans that this effect is mediated by the formation of [(GS)2AsSe]- , the seleno-bis(S-glutathionyl) arsinium ion, which is then rapidly excreted via the hepatobiliary system. Concurrently, two Phase II studies in China and Bangladesh have suggested clinical benefit to selenium supplementation in arsenicosis patients. Objective: To assess whether daily selenium supplementation counters arsenic toxicity in patients exposed to drinking water arsenic. If proven effective, selenium supplementation might be safely and cost-effectively implemented in the worst-affected localities.

NCT ID: NCT01335581 Completed - Clinical trials for Refractory Mixed Type Melasma

Study of Laser Treatment of Melasma

Start date: April 2011
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the RevLite laser in the treatment of refractory mixed type melasma.

NCT ID: NCT01092884 Completed - Melasma Clinical Trials

Polypodium Leucotomos Extract for the Treatment of Melasma

Start date: March 2010
Phase: N/A
Study type: Interventional

We will assess whether oral supplementation with Polypodium leucotomos, a commercially marketed fern extract, improves facial melasma in Hispanic women with moderate to severe melasma. Subjects will be randomized to either Group 1, which will receive oral Polypodium leucotomos extract plus topical sunscreen, or Group 2, which will receive oral placebo plus topical sunscreen. The study will last 12 weeks, and we hypothesize that the Polypodium leucotomos group will have more improvement in their melasma compared to the placebo group.

NCT ID: NCT00927771 Recruiting - Melanosis Clinical Trials

Azelaic Acid Versus Hydroquinone in Melasma

Start date: June 2009
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare the safety and effectiveness of Azelaic Acid Gel to Hydroquinone Cream in the treatment of melasma.

NCT ID: NCT00863278 Terminated - Melanosis Clinical Trials

Treatment of Melasma With Stabilized Kligman Preparation Associated or Not With Pulsed Dye Laser

Start date: March 2009
Phase: Phase 4
Study type: Interventional

Melasma is an acquired disorder of pigmentation that leads to irregular pigmented patches on the face. Treatment is difficult and to date the best treatment option is the combination of hydroquinone, retinoic acid and steroids combined in topical daily application (called Kligman's trio). Q-switched pigmentary lasers are usually ineffective and can induce post inflammatory hyperpigmentation (PIH). Intense pulsed light can sometimes improve melasma but also induce PIH which limit their use. Recently, pulsed dye laser were demonstrated to be effective in treating some pigmentary defects. Associating blanching cream with hydroquinone to prevent PIH after laser or intense pulsed light has been already reported with success. The objective of the study is to compare in a prospective intra individual comparative trial the association of pulsed dye laser plus stabilized Kligman's trio to Kligman's trio alone. The secondary objective was to study the frequency and the intensity of the potential side effects including PIH.

NCT ID: NCT00717652 Suspended - Melasma Clinical Trials

Efficiency And Safety Of Association Arbutin, Triamcinolone And Tretinoin In Treatment Of Melasma

melasma
Start date: July 2008
Phase: Phase 2/Phase 3
Study type: Interventional

The objective of this study is evaluating the clinical activity of the association (tretinoin + arbutin + triamcinolone) in the treatment of epidermal melasma.